Navigation Links
Alexza to Announce 2007 Financial Results and Update Its Clinical Pipeline on Monday, March 17, 2008
Date:3/12/2008

tion of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato(R) system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.

Alexza has six product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing. AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches has completed Phase 2 testing. AZ-104 (Staccato loxapine) for the acute treatment of migraine headaches and AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder are in Phase 2 testing. Product candidates in Phase 1 testing include AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain, which is partnered with Endo Pharmaceuticals in North America, and AZ-007 (Staccato zaleplon) for the treatment of insomnia. More information, including this and past press releases from Alexza is available online at http://www.alexza.com.

Safe Harbor Statement

The anticipated conference call will contain forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs. The Company's forward-looking statements also involve assump
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
2. Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
3. Alexzas Corporate Presentation to be Webcast at the 10th Annual BIO CEO & Investor Conference
4. Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference to Webcast Alexzas Corporate Presentation
5. Alexza Announces Partnership With Endo for AZ-003 (Staccato(R) fentanyl) in North America
6. Alexza Elects Dr. Hal V. Barron to Its Board of Directors
7. 19th Annual Piper Jaffray Health Care Conference to Webcast Alexzas Corporate Presentation
8. The 4th Annual BIO Investor Forum to Webcast Alexzas Corporate Presentation
9. Nile Therapeutics to Announce 2007 Fourth Quarter and Full Year Financial Results on Thursday, March 13, 2008
10. DMetrix and the Armed Forces Radiobiology Research Institute Announce Cooperative Research and Development Agreement
11. Raven Announces RAV12 Phase 1/2a Study Results To Be Presented at ASCO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... high-quality recombinant antibodies, announced today that the National Institutes of Health (NIH) has ... which will be administered by the NIH’s National Institute of Diabetes and Digestive ...
(Date:9/1/2015)... 2015 The Dohmen Company today announced ... MBA as Chief Science Officer (CSO) of Dohmen ... role, Dr. Floyd will lead Dohmen,s growing regulatory ... pre-commercial and post approval outsourced services in quality, ... Dr. Floyd brings decades of experience leading global ...
(Date:9/1/2015)... , ... September 01, 2015 , ... Knowledgent , ... highlights the opportunities for advanced analytics utilizing data lakes in the healthcare industry. , ... has seen an explosion of data over the last few years as more entities ...
(Date:9/1/2015)... ... September 01, 2015 , ... Industry leader iLab Solutions recently ... this newly-created position, Gibbs will lead iLab’s business operations in the region, with ... This entails not only introducing iLab to potential partners but support and management ...
Breaking Biology Technology:AxioMx Announces Receipt of SBIR Grant for DNA-Protein Complex Antigen Development 2AxioMx Announces Receipt of SBIR Grant for DNA-Protein Complex Antigen Development 3Dohmen Life Science Services Appoints Eric Floyd, Ph.D. as Chief Science Officer 2Dohmen Life Science Services Appoints Eric Floyd, Ph.D. as Chief Science Officer 3New White Paper Explores Data Lake Opportunities in the Healthcare Industry 2iLab Solutions Hires Gerard Gibbs, Director of Business Development, Asia Pacific 2iLab Solutions Hires Gerard Gibbs, Director of Business Development, Asia Pacific 3
... 2011 VIVUS, Inc. (Nasdaq: VVUS ), ... therapeutic products, today reported its financial results for the first quarter ... the quarter ended March 31, 2011, VIVUS reported a net loss ... net loss of $18.8 million or $0.23 per share for the ...
... 2, 2011 Richard Resnick, GenomeQuest,s chief executive ... May 3, 2011, at the Biomarker World Congress ... Sequencing on Companion Diagnostics" for pharmaceutical and biotechnology ... and data management technologies. The Biomarker ...
... 2, 2011 Dyadic International, Inc. ("Dyadic") (OTC ... the discovery, development, manufacture and sale of enzyme ... industrial enzyme industries, announced today that its research ... has entered into a research agreement with Sanofi ...
Cached Biology Technology:VIVUS Reports First Quarter 2011 Financial Results 2VIVUS Reports First Quarter 2011 Financial Results 3VIVUS Reports First Quarter 2011 Financial Results 4VIVUS Reports First Quarter 2011 Financial Results 5GenomeQuest to Lead Biomarker World Congress Panel on Applying Whole Genome Sequencing to Developing Companion Diagnostics 2Dyadic Netherlands Enters Into R&D Collaboration With Sanofi Pasteur and EnGen Bio 2
(Date:9/1/2015)... Calif. , Sept. 1, 2015  Automation ... travelers during airport passenger screening. This is the ... passenger screening process will become unintrusive. An assortment ... based on voluntary background investigations will transform the ... Frost & Sullivan, Global Airport Passenger Screening ...
(Date:8/31/2015)... BURNABY, Canada , August 31, 2015 ... use of biometrics technology in government digitization projects to drive ... According to a recently published TechSci Research report, " India ... India is projected to grow at ... in the market is anticipated on account of extensive use ...
(Date:8/31/2015)... , Aug. 31, 2015 Research and Markets ... "Saudi Arabia Biomedical Sensors Market - Growth, Trends ... The Saudi Arabia Biomedical Sensors market is ... of 3.64% over the period 2014-2020 The ... to the genetic formulation of each individual. These sensors ...
Breaking Biology News(10 mins):The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 2The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 3The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 4India Biometrics Market to Grow at Over 35% Through 2020, Says TechSci Research 2India Biometrics Market to Grow at Over 35% Through 2020, Says TechSci Research 3Saudi Arabia Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts (2014-2020) 2
... look cute. They have a thick fur, fly somewhat ... They are very much appreciated by farmers as keen ... honeybee populations, the buff-tailed bumblebee, Bombus terrestris , ... pollination of fruit and vegetable crops both inside and ...
... Israel decades ago, but worldwide the disease continues to ... people worldwide and killed an estimated 660,000, mostly African ... extent focused on advanced science and vaccine development. But ... Jerusalem believe a parallel approach -- based on methods ...
... REDDING, Calif.As trees grow larger in even-aged stands, competition ... for soil moisture, nutrients, and sunlight. Competition also increases ... leads to a buildup of dead fuels. A recent ... the U.S. Forest Service,s Pacific Southwest Research Station, considered ...
Cached Biology News:Peaceful bumblebee becomes invasive 2Peaceful bumblebee becomes invasive 3Malaria conference looks to Israel's past for modern solutions 2Lowering stand density reduces mortality of ponderosa pine stands 2
Anti Autotaxin /ENPP2 , - (Rabbit)...
... 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose Pale yellow solid. An N-nitroso-containing ... nitric oxide donor in pancreatic islets. ... Causes DNA alkylation and DNA strand ... ≥95% by HPLC. Soluble in H ...
Mouse monoclonal antibody to CDC2L5 - cell division cycle 2-like 5 (cholinesterase-related cell division controller)...
... The pACHLT-A-BFP Baculovirus Transfer Vector is a derivative ... the gene for blue fluorescent protein (BFP), followed ... site (MCS).,Foreign genes are expressed as BFP-6xHis fusion ... restriction enzyme,sites (EcoR I, Stu I, Sac I, ...
Biology Products: